Ortiz Justin Orlando, Potter Anna K, Benmerzouga Imaan
Kiran C. Patel College of Osteopathic Medicine, Department of Foundational Sciences, Clearwater, FL, USA.
Res Rep Trop Med. 2025 Mar 29;16:25-30. doi: 10.2147/RRTM.S431290. eCollection 2025.
is a world-wide parasite, with an estimated prevalence of approximately 30%. Toxoplasmosis is a severe disease in the immunocompromised, but few symptoms are exhibited by patients with an intact immune system, making this parasite a worldwide burden. Currently, few drugs exist in treating acute toxoplasmosis and no drugs exist to eliminate the bradyzoite of . Effective therapies against acute and chronic toxoplasmosis are urgently needed to reduce the burden of this disease. This review aims to give a summary of recent findings in the bradyzoite form of and the implication of these findings on drug development. A thorough search of PubMed and Google Scholar databases was used to identify studies within the past 10 years that illustrate targetable key elements in the differentiation and formation of the bradyzoite form of
是一种全球范围内的寄生虫，估计流行率约为30%。弓形虫病在免疫功能低下者中是一种严重疾病，但免疫系统完好的患者很少表现出症状，这使得这种寄生虫成为全球的一个负担。目前，治疗急性弓形虫病的药物很少，而且没有药物可以消除的缓殖子。迫切需要有效的急性和慢性弓形虫病治疗方法来减轻这种疾病的负担。本综述旨在总结关于缓殖子形式的最新研究结果以及这些发现对药物开发的意义。通过全面检索PubMed和谷歌学术数据库，以确定过去10年内阐述缓殖子形式的分化和形成中可作为靶点的关键要素的研究
